EyePoint (EYPT) Acquisitions (2018)

EyePoint (EYPT) posted Acquisitions of $16.8 million for Q3 2018, up 200.0% sequentially from -$16.8 million in Q2 2018.

EyePoint (EYPT) Acquisitions (2018) Analysis & Trends

EyePoint has reported Acquisitions for 1 years, with the latest figure at $16.8 million in Q3 2018.

Quarterly Acquisitions changed N/A year-over-year to $16.8 million in Q3 2018, while the trailing twelve-month figure through Sep 2019 was $16.8 million (up 11.33% YoY) and the FY2018 annual result came in at $16.8 million, changed N/A from the prior year.
Acquisitions climbed to $16.8 million in Q3 2018 per EYPT's latest filing, from -$16.8 million in the prior quarter.
Over five years, Acquisitions peaked at $16.8 million in Q3 2018 and troughed at -$16.8 million in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	EyePoint	1.25 Bn	1.07 Bn	507,000.00	-

Download Data